An oncolytic herpes simplex virus armed with IL-12 for treatment of preclinical glioblastoma

Glioblastoma (GBM) is a devastating brain cancer with a 5-year survival rate of ∼5% despite current treatment regimens. Multiple oncolytic herpes simplex viruses (oHSV) have been designed for GBM therapy, but clinical trials have thus far met with limited success. A potential reason for this lack of...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Joseph W. Jackson, Bonnie L. Hall, Chaim Sneiderman, Amy Webb, Trevor J. Hancock, Marina Vlasyuk, Lisa Bailey, Molly Xiaokui, Isaac H. Solomon, Keith Ligon, William F. Goins, Gary Kohanbash, E. Antonio Chiocca, Joseph C. Glorioso
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2025-09-01
Edice:	Molecular Therapy: Oncology
Témata:	HSV oncolytic GBM cancer immunotherapy
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2950329925000992
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!